Dominion Aesthetic Technologies, a Houston, TX-based medical device company, closed a $23.7M Series B financing.

The round was led by Dominion Aesthetic Technologies’ CEO, Cooper Collins, with participation from Houston’s top biotechnology and medical device investors, including MagnaSci Ventures, McNair Interests Ltd, and Morton Cohn Investments.

The company intends to use the funds to accelerate the manufacturing and commercialization of its EON.

The closing of this Series B round follows the relocation from San Antonio to its Houston headquarters this month. The new corporate office, located within 5 minutes of the Houston Bush Intercontinental Airport, is in a Qualified Opportunity Zone.

Dominion Aesthetic Technologies is advancing EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasive lipolysis of the abdomen. EON’s treatment head combines a laser, which heats adipose tissue to induce apoptosis, with a jet-inspired impingement cooling system that protects the skin and provides patient comfort. The microprocessor-controlled articulated robotic arm delivers consistent applications of laser energy over the designated treatment area.